Ginkgo Q1 revenue $168M (+282% YoY); raises FY22 total revenue guidance to $375-390M

Ginkgo Bioworks Holdings, Inc.

2023-Q1 EPS reported -$0.37 revenue$168,405,000

Total revenue $168M (+282% YoY); Foundry revenue $21M (-5% YoY); Biosecurity revenue $147M.
Loss from operations $(675)M incl. $659M stock comp; Adj. EBITDA $(2)M improved from $(51)M.
Added 11 new Cell Programs in Q1; FY22 target of 60 new programs unchanged.
Raised FY22 total revenue guidance to $375-390M from $325-340M; Foundry guidance unchanged.
Announced plans to acquire Bayer's West Sacramento ag biologics site and flagship collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.